Advanced Microbubbles

Executive Summary

Advanced Microbubbles (AMB Labs) is a private US-based company specializing in the manufacture of size-isolated, monodisperse microbubbles for biomedical and physical sciences research. Founded in 2015 and headquartered in Newark, the company addresses a critical need in ultrasound imaging and targeted drug delivery by providing highly uniform microbubbles that enhance reproducibility and performance in preclinical studies. Their technology enables precise control over bubble size and shell composition, which is essential for applications ranging from contrast-enhanced ultrasound to therapeutic payload delivery. While the company currently serves the research market, its proprietary manufacturing process positions it as a potential partner for pharmaceutical and biotechnology firms developing microbubble-based diagnostics or therapeutics. The overall market for microbubbles is growing, driven by advances in non-invasive imaging and localized drug release, but AMB Labs faces competition from established players and academia. The company's private status and lack of disclosed funding or revenue data make it difficult to assess commercial traction, but its niche focus on monodisperse bubbles offers a differentiated value proposition. As the field matures, AMB Labs could capture a significant share of the research supply segment and eventually pivot to clinical applications, though significant regulatory and scaling hurdles remain.

Upcoming Catalysts (preview)

• Q1 2028Launch of next-generation drug delivery microbubble platform50% success
• Q3 2027Strategic partnership with pharmaceutical company for preclinical studies40% success
• Q4 2026Expansion into European research market via distributor agreement60% success